Cyxone AB has signed an agreement regarding the right to acquire the clinical pharmaceutical candidate Rabeximod from OxyPharma AB. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue to enable the completion of the acquisition and a phase 2b study within rheumatoid arthritis.
Cyxone is a biopharmaceutical company that develops pharmaceuticals within autoimmune diseases.
Lindahl assisted Cyxone through Anders Burén (life science).
Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.
Essential Cookies
These cookies are necessary for the functionality of the site and cannot be disabled.
Analytics Cookies>
We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.